Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients
Condition: Recurrent Nasopharyngeal Carcinoma Interventions: Drug: PD-1 blocking antibody; Radiation: IMRT Sponsor: Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Intensity-Modulated Radiation Therapy | Nasopharyngeal Cancer | Research